Merck Clinical Trials Logo Merck Clinical Trials

Clinical Trials

Merck Clinical Trials
  • About clinical trials
    • About Clinical Trials
    • How does participation work?
    • What to consider
    • Frequently asked questions
  • Resources
    • Resources
    • For patients
    • For caregivers
  • Our medical science
  • For HCPs
  • English
    • Back
    • English
    • Español

Trial Drug: MK-6194-matching placebo

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of MK-6194 in participants with active UC.

A Study of MK-6194 in Participants With Active Ulcerative Colitis

November 12, 2021

By clique_admin

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of MK-6194 in participants with active UC.

Merck Clinical Trials Logo Merck Clinical Trials
  • Merck.com
  • Privacy Policy
  • Terms of Use
  • Policies & Perspectives
  • Cookie Preferences
  • Accessibility

Copyright © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.

THIS WEBSITE IS INTENDED FOR A UNITED STATES AUDIENCE ONLY

Merck Essential Accessibility

Merck Essential Accessibility